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Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by formation of chronic,
organized thrombus in pulmonary arteries resulting in development of pulmonary hypertension. We
describe the favorable recovery of a patient with inoperable CTEPH treated with combination riociguat
and inhaled treprostinil.
The patient is a 77 year old female who presented with bilateral pulmonary emboli and was anti-
coagulated with warfarin for six months. One year later the patient developed recurrent dyspnea and
multiple bilateral pulmonary emboli were again noted. Pulmonary arterial pressure (PAP) was estimated
at 91 mmHg by echocardiography. The patient was treated with warfarin and sildenaﬁl. Eighteen months
later the PAP was estimated at 106 mmHg with signiﬁcant right ventricular enlargement. The patient was
referred to our center for pulmonary hypertension consultation. Right heart catheterization conﬁrmed
severe pulmonary hypertension with preserved cardiac output. The patient was not a candidate for
thromboendarterectomy due to the peripheral location of chronic obstructing thrombi. Systemic pros-
tacyclin therapy was declined by the patient. Inhaled treprostinil was added to sildenaﬁl and warfarin.
The patient maintained good performance status for 2 years, but then developed progressive activity
limitation with depressed cardiac output on right heart catheterization. Systemic prostacyclin therapy
was declined again. Sildenaﬁl was replaced with riociguat, and 1 year later the patient demonstrated
signiﬁcant recovery of functional capacity and improved hemodynamic proﬁle.
We describe signiﬁcant recovery in a patient with inoperable, progressive CTEPH treated with rioci-
guat and inhaled treprostinil after failing sequential addition of sildenaﬁl and inhaled treprostinil to
warfarin. The reported beneﬁts may relate to riociguat's ability to directly stimulate production of cyclic
GMP independent of nitric oxide levels in pulmonary artery smooth muscle. There may also be a unique
interaction between riocguat and treprostinil that enhanced treatment outcome. Further investigation of
this combination of agents may be warranted.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a
consequence of blood ﬂow limitation by persistant, organizedher), delliott@southcollegetn.
Ltd. This is an open access article uthrombus in the pulmonary arterial circulation following pulmo-
nary thromboembolism. CTEPH is categorized as WHO Group 4 in
the World Health Organization classiﬁcation of pulmonary hyper-
tensive diseases [1]. Historically, treatment options for CTEPH have
included surgical thromboendarterectomy or off-label use of pul-
monary arterial vasodilators approved for the treatment of WHO
Group I pulmonary arterial hypertension (PAH). Pulmonary end-
arterectomy (PEA) can signiﬁcantly improve pulmonary vascular
resistance and functional capacity [2]. However, many patients arender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sistant pulmonary hypertension after PEA [3]. While several agents
have been approved by the Federal Drug Administration (FDA) for
treatment of PAH, FDA-approved options for medical therapy of
CTEPH remain limited to one agent, riociguat [4]. There have been
far fewer clinical trials designed to examine the efﬁcacy of targeted
therapies in CTEPH. Further, although there is heightened interest
in a combination therapy approach to treating PAH, the potential
role of combination pharmacotherapy in the treatment of CTEPH is
largely unknown.
We report the favorable outcome of a patient with inoperable
CTEPH who was treated with combination riociguat and inhaled
treprostinil after disease progression on sildenaﬁl alone and with
combination sildenaﬁl and inhaled treprostinil.
2. Case report
Our patient was a 77 year old female who was diagnosed with
moderate pulmonary hypertension (estimated right ventricular
systolic pressure 50e60 mmHg) by echocardiography at the time of
an initial thromboembolic event resulting in bilateral pulmonary
emboli. She was anticoagulated with warfarin for 6 months and
regained normal functional capacity. She developed exertional
dyspnea one year following the initial thromboembolism. Multiple
bilateral pulmonary emboli were identiﬁed once again, and treat-
ment with warfarin reinitiated. After this second event, the pa-
tient's estimated pulmonary artery pressurewasmarkedly elevated
at 91 mmHg by echocardiography. Three months later there were
no clinical improvements in dyspnea, echocardiographic or radio-
logic ﬁndings. The patient reported NYHA functional class 4
symptoms. Sildenaﬁl was added to warfarin (Month 0, Fig. 1). The
patient experienced some improvement in dyspnea (NYHA func-
tional class 3) in the following months. Echocardiography was
repeated after 18 months of treatment with sildenaﬁl and warfarin.
The estimated pulmonary artery pressure was even higher at
106 mmHg and right ventricular enlargement had become
apparent. At this point, the patient was referred to our center for a
pulmonary hypertension consultation.Fig. 1. Change in NHYA functional class.
Table 1
Treatment effects.
6 MW (m)
Sildenaﬁl alone 24 months(Treprostinil added) 405
Sildenaﬁl þ treprostinil 30 months(Riociguat replaced sildenaﬁl) 0
Treprostinil þ riociguat 12 months 400During the initial pulmonary hypertension evaluation, the pa-
tient reported NYHA functional class 3 symptoms and was able to
walk 405 m in 6 minutes. A ventilation perfusion scan revealed
persistant peripheral perfusion defects. Right heart catheterization
was performed conﬁrming severe pulmonary hypertension. The
pulmonary artery pressure was severely elevated at 102/34/
58 mmHg, although cardiac output and cardiac index remained
within normal range (Table 1, Sildenaﬁl alone). In light of right
ventricular enlargement noted by echocardiography and the severe
degree of pulmonary artery pressure elevation, systemic prosta-
cyclin therapy was recommended. The peripheral perfusion ab-
normalities on ventilation perfusion scanning were not considered
amenable to thromboendarterectomy. The patient expressed
reluctance to systemic prostacyclin treatment, so inhaled trepros-
tinil was added to sildenaﬁl (Month 24, Fig. 1).
The addition of inhaled treprostinil to sildenaﬁl resulted in
signiﬁcant improvement in functional class over the next 24
months (Fig. 1). Six minute walk distance increased to 475 m over
the next 6 months. The patient suffered a toe fracture and was
unable to complete a 6 minute walk for several months thereafter.
She began to reportmore exertional dyspnea and activity limitation
after 24 months on the sildenaﬁl-inhaled treprostinil combination.
By month 30 on this combination she was unable to perform a 6
minute walk due to severe breathlessness and fatigue. She reported
NYHA functional class 4 symptoms (Fig. 1) and was requiring
continuous use of supplemental oxygen.
Right heart catheterization was repeated (Table 1,
Sildenaﬁl þ Treprostinil). Although the PA pressure was similar to
the previous study, there had been a substantial decline in cardiac
output and index. Systemic prostacyclin therapy was again rec-
ommended, but the patient remained reluctant. As an alternative,
riociguat was substituted for sildenaﬁl on a trial basis.
After the initiation of riociguat-inhaled treprostinil, the patient
experienced a signiﬁcant improvement in activity tolerance (Fig. 1).
The patient regained NYHA functional class 2 activity tolerance and
by 12 months was walking 400 m in 6 minutes. Right heart cath-
eterization was repeated at 12 months on the riociguat-inhaled
treprostinil combination. Improvements were noted in pulmo-
nary artery pressure, cardiac output and cardiac index as noted in
Table 1 (Treprostinil þ Riociguat). This combination of agents
effected improvements in activity tolerance and hemodynamics
after failure on sildenaﬁl-inhaled treprostinil.3. Discussion
In this report we describe the outcome of a patient with non-
operable and progressive CTEPH who was initially treated with
sildenaﬁl. Sildenaﬁl provided some relief of symptoms and seemed
to limit progression for a period of time. However, signs of pro-
gression began to appear on echocardiogram leading to the addi-
tion of inhaled treprostinil to sildenaﬁl. This treatment regimen
resulted in improvement of functional capacity, but ultimately
progression of the disease process was noted with signiﬁcant right
ventricular compromise. The substitution of the soluble guanylate
cyclase stimulator, riociguat, for sildenaﬁl subsequently led to
improvement in functional class, 6 minute walk distance andFC RA (mmHg) PA (mmHg) CO (L/min) CI (L/min/m2)
3 12 102/34/58 6.5 3.2
4 16 101/36/59 4.02 2.04
2 15 92/28/49 4.5 2.28
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Riociguat is a soluble guanylate cyclase stimulator approved by
the FDA for treatment of pulmonary arterial hypertension (PAH)
and chronic thromboembolic pulmonary hypertension (CTEPH) in
2013. This agent is the ﬁrst in a new PAH treatment class. Riociguat
is the ﬁrst and only treatment agent approved speciﬁcally for
treating CTEPH to date. The pathogenesis of PAH is known to
depend, in part, on the pulmonary vascular nitric oxide pathway
[5]. Nitric oxide is an endogenous vasodilator produced by the
conversion of arginine to nitric oxide under the inﬂuence of nitric
oxide synthase in pulmonary vascular endothelial cells. Nitric oxide
diffuses to the vascular smooth muscle where it catalyzes the for-
mation of cyclic guanylate monophosphate (cGMP) by guanylate
cyclase. Cyclic GMP then effects smooth muscle relaxation and
regulation of cellular proliferation and inﬂammation in the vessel
wall [6]. The pathogenesis of PAH is known to involve a deﬁciency
of nitric oxide synthase in pulmonary vascular endothelial cells. The
resulting deﬁciency of NO production limits vascular smooth
muscle relaxation and regulation of other cellular activities in the
vessel wall.
Riociguat enhances the formation of cGMP in pulmonary
vascular smooth muscle similar to the effect of endogenous nitric
oxide (NO) although by a different mechanism. This effect is ach-
ieved by directly stimulating guanylate cyclase and by making
guanylate cyclase more sensitive to NO [7]. Phosphodiesterase 5
(PDE5) inhibitors have been shown to augment the effect of low NO
production in PAH by preventing the degradation of cGMP [8]. As
such, the impact of PDE5 inhibitor action on the nitric oxide
pathway is dependent on the amount of NO produced, whereas,
riociguat action is independent of endogenous NO production.
Our patient had been treated with the PDE5 inhibitor, sildenaﬁl,
initially. As her disease progressed, inhaled treprostinil was added
to sildenaﬁl. This combination resulted in signiﬁcant, but tempo-
rary, improvement in the prognostic indicators, 6 minute walk
distance and WHO functional class. Hemodynamic parameters did
not improve. In fact, both functional and hemodynamic parameters
deteriorated over time. The substitution of riociquat for sildenaﬁl
resulted in a restoration of functional capacity, oxygenation and
improvement in hemodynamics. While systemic prostacyclin
therapy was recommended after progression on the combination of
sildenaﬁl and inhaled treprostinil, the effects of combination rio-
ciguat and inhaled treprostinil allowed delay of this more compli-
cated form of treatment.
Recent literature has reported beneﬁt when agents from the
different pathways known to effect the pathophysiology of PAH are
combined. As an example, the addition of sildenaﬁl to long-term
intravenous epoprostenol therapy has been shown to improve ex-
ercise capacity, hemodynamics, quality of life and time to clinicalworsening [9]. We saw an initial beneﬁt when treprostinil was
added to sildenaﬁl, although the effect faded with time. We then
observed signiﬁcant clinical improvements when riociguat was
substituted for sildenaﬁl in the combination regimen with tre-
prostinil. Hoeper et al. have reported improvements in 6 minute
walk distance, hemodynamics, NT-proBNP levels, and WHO func-
tional class in PAH patients with an inadequate response to PDE5
inhibitor therapy and then transitioned to riociguat [10]. Further,
patients in the Patent 1 trial demonstrated signiﬁcant improve-
ment when riociquat was added to existing prostacyclin therapy
[11]. The improvements our patient experienced were clearly
associated with the substitution of riociguat in the treatment
regimen and provided clinical beneﬁt not achieved with the com-
bination of sildenaﬁl and inhaled treprostinil. The clinical im-
provements in our patient after substitution of riociguat for
sildenaﬁl were likely due to the fact that riociguat is not dependent
on endogenous NO levels, but rather provides an effective substi-
tute for the effect of NO on cGMP production. Further investigation
of riociguat-prostacyclin combination therapy in CTEPH treatment
may be warranted as there are many patients who are not candi-
dates for surgical endarterectomy.
The patient described in this report provided consent to publish
an account of her experience with chronic thromboembolic pul-
monary hypertension and its treatment.References
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